In fact, we have shown through animal studies that genetic and pharmacological activation of NRF2 ameliorates many pathological conditions, such as multiple sclerosis [18], chronic obstructive pulmonary disease (COPD) [19], Alzheimer’s diseases [20], diabetes mellitus [21], and sickle cell disease (SCD) [22,23]. This evidence concerns the gene NFE2L2 and multiple sclerosis.